Improving treatment for superwarfarin poisoning using bile sequestrants
Optimization of Bile Sequestrants to Treat Superwarfarin Poisoning
This study is looking at how well a medication called cholestyramine can help people who have been poisoned by superwarfarins, which are strong blood thinners, by stopping the poison from being absorbed in the body and improving their chances of recovery.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10908479 on NIH RePORTER |
What this research studies
This research focuses on optimizing the use of bile sequestrants, specifically cholestyramine, to treat poisoning caused by superwarfarins, which are highly potent anticoagulants. The study aims to enhance the effectiveness of current treatments that primarily involve Vitamin K1, which does not eliminate the toxin from the body. By preventing the reabsorption of the poison through the digestive system, the research seeks to significantly improve survival rates and reduce long-term health complications associated with superwarfarin exposure. The approach is based on previous findings that demonstrated a marked increase in survival rates in animal models treated with cholestyramine.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals of all ages who have been accidentally or intentionally poisoned by superwarfarins.
Not a fit: Patients who have not been exposed to superwarfarins or those with contraindications to cholestyramine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for superwarfarin poisoning, significantly improving patient outcomes and reducing healthcare costs.
How similar studies have performed: Previous studies have shown promising results with cholestyramine in animal models, indicating potential for success in human applications.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Feinstein, Douglas L. — University of Illinois at Chicago
- Study coordinator: Feinstein, Douglas L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.